Mechanism for complement-mediated, antibody-dependent enhancement of human immunodeficiency virus type 1 infection in MT2 cells is enhanced entry through CD4, CD21, and CXCR4 chemokine receptors

Viral Immunology

Volumn 19, Issue 3, 2006, Pages 434-447

  Robinson Jr , W Edward ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CHEMOKINE RECEPTOR CXCR4; CHEMOKINE RECEPTOR CXCR4 ANTAGONIST; COMPLEMENT; COMPLEMENT COMPONENT C3D RECEPTOR; COMPLEMENT RECEPTOR; COMPLEMENTARY DNA; EFAVIRENZ; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; IMMUNOGLOBULIN ANTIBODY; INDINAVIR; JM 2987; OKT 4; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; UNCLASSIFIED DRUG; ZIDOVUDINE;

CLADISTICS; COMPLEMENT ACTIVATION; COMPLEMENT MEDIATED ANTIBODY DEPENDENT ENHANCEMENT; CONFERENCE PAPER; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NUCLEOTIDE SEQUENCE; OPSONIZATION; PROVIRUS; VIRION; VIRUS CELL INTERACTION; VIRUS DNA CELL DNA INTERACTION; VIRUS NEUTRALIZATION; VIRUS REPLICATION; VIRUS VIRULENCE;

ANTIBODY-DEPENDENT ENHANCEMENT; ANTIGENS, CD4; CD4-POSITIVE T-LYMPHOCYTES; CELL LINE, TRANSFORMED; CELL TRANSFORMATION, VIRAL; COMPLEMENT SYSTEM PROTEINS; HIV ANTIBODIES; HIV-1; HUMANS; RECEPTORS, COMPLEMENT 3D; RECEPTORS, CXCR4;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 33750952525     PISSN: 08828245     EISSN: None     Source Type: Journal    
DOI: 10.1089/vim.2006.19.434     Document Type: Conference Paper

References (55)

1. Auewarakul P, Louisirirotchanakul S, Sutthent R, Taechowisan T, Kanoksinsombat C, and Wasi C: Analysis of neutralizing and enhancing antibodies to human immunodeficiency virus type 1 primary isolates in plasma of individuals infected with env genetic subtype B and E viruses in Thailand. Viral Immunol. 1996;9:175-185.
2. Baba M, Nishimura O, Kanzaki N, Okamoto M, Sawada H, Iizawa Y, Shiraishi M, Aramaki Y, Okonogi K, Ogawa Y, Meguro K, and Fujino M: A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity. Proc. Natl. Acad. Sci. U.S.A. 1999;96:5698-5703.
3. Banhegyi D, Bacsi A, Toth FD, Prohaszka Z, Horvath A, Beck Z, Konya J, and Fust G: Significant decrease of the enhancement/neutralization index in HIV patients during highly active antiretroviral therapy (HAART). Immunol. Lett. 2003;89:25-30.
4. Bouhlal H, Chomont N, Haeffner-Cavaillon N, Kazatchkine MD, Belec L, and Hocini H: Opsonization of HIV-1 by semen complement enhances infection of human epithelial cells. J. Immunol. 2002;169:3301-3306.
5. Bridger GJ, Skerlj RT, Thornton D, Padmanabhan S, Martellucci SA, Henson GW, Abrams MJ, Yamamoto N, De Vreese K, Pauwels R, and deClercq E: Synthesis and structure-activity relationships of phenylenebis(methylene)-linked bis-tetraazamacrocycles that inhibit HIV replication: Effects of macrocyclic ring size and substituents on the aromatic linker. J. Med. Chem. 1995;38:366-378.
6. Doepper S, Kacani L, Falkensammer B, Dierich MP, and Stoiber H: Complement receptors in HIV infection. Curr. Mol. Med. 2002;2:703-711.
7. Doepper S, Stoiber H, Kacani L, Sprinzl G, Steindl F, Prodinger WM, and Dierich MP: B cell-mediated infection of stimulated and unstimulated autologous T lymphocytes with HIV-1: Role of complement. Immunobiology 2000;202:293-305.
8. Dopper S, Wilflingseder D, Prodinger WM, Stiegler G, Speth C, Dierich MP, and Stoiber H: Mechanism(s) promoting HIV-1 infection of primary unstimulated T lymphocytes in autologous B cell/T cell co-cultures. Eur. J. Immunol. 2003;33:2098-2107.
9. Ebenbichler CF, Thielens NM, Vornhagen R, Marschang P, Arlaud GJ, and Dierich MP: Human immunodeficiency virus type 1 activates the classical pathway of complement by direct C1 binding through specific sites in the transmembrane glycoprotein gp41. J. Exp. Med. 1991;174:1417-1424.
10. Forthal DN, Landucci G, Gorny MK, Zolla-Pazner S, and Robinson WE Jr: Functional activities of 20 human immunodeficiency virus type 1 (HIV-1) specific human monoclonal antibodies. AIDS Res. Hum. Retroviruses 1995;11:1095-1099.
11. Freissmuth D, Dierich MP, and Stoiber H: Role of complement in the pathogenesis of SIV infection. Front. Biosci. 2003;8:s733-s739.
12. Füst G: Enhancing antibodies in HIV infection. Parasitology 1997;115(Suppl.):S127-S140.
13. Gardner M, Rosenthal A, Jennings M, Yee JA, Antipa L, and Robinson JE: Passive immunization of rhesus macaques against SIV infection and disease. AIDS Res. Hum. Retroviruses 1995;11:843-854.
14. Gardner MB, Rosenthal A, Jennings M, Yee J, Antipa L, and MacKenzie M: Passive immunization of macaques against SIV infection. J. Med. Primatol. 1994;23:164-174.
15. Haigwood NL, Montefiori DC, Sutton WF, McClure J, Watson AJ, Voss G, Hirsch VM, Richardson BA, Letvin NL, Hu SL, and Johnson PR: Passive immunotherapy in simian immunodeficiency virus-infected macaques accelerates the development of neutralizing antibodies. J. Virol. 2004;78:5983-5995.
16. June RA, Schade SZ, Bankowski MJ, Kuhns M, McNamara A, Lint TF, Landay AL, and Spear GT: Complement and antibody mediate enhancement of HIV infection by increasing virus binding and provirus formation. AIDS 1991;5:269-274.
17. Kellogg DE, and Kwok S: Detection of human immunodeficiency virus. In: Innis MA, Gelfand DH, Sninsky JJ, and White TJ (eds.). PCR Protocols: A Guide to Methods and Applications, pp. 337-347. Academic Press, San Diego, CA, 1990.
18. King PJ, Lee DJ, Reinke RA, Victoria JG, Beale K, and Robinson WE Jr: Human immunodeficiency virus type 1 integrase containing a glycine to serine mutation at position 140 is attenuated for catalysis and resistant to integrase inhibitors. Virology 2003;306:147-161.
19. King PJ, McDougall BR, Tenner AJ, and Robinson WE Jr: Amino acids 603-622 of simian immunodeficiency virus transmembrane glycoprotein bind complement component C1q leading to subsequent deposition of complement component C3 and increased infectivity of cell lines expressing CD4 and CR2. Pathogenesis 1997;1:43-56.
20. Lee DJ, and Robinson WE Jr: Human immunodeficiency virus type 1 (HIV-1) integrase: Resistance to diketoacid integrase inhibitors impairs HIV-1 replication, integration, and confers cross-resistance to L-chicoric acid. J. Virol. 2004;78:5835-5847.
21. Lund O, Hansen J, Soorensen AM, Mosekilde E, Nielsen JO, and Hansen JE: Increased adhesion as a mechanism of antibody-dependent and antibody-independent complement-mediated enhancement of human immunodeficiency virus infection. J. Virol. 1995;69:2393-2400.
22. McDougal JS, Mawle A, Cort SP, Nicholson JK, Cross GD, Scheppler-Campbell JA, Hicks D, and Sligh J: Cellular tropism of the human retrovirus HTLV-III/LAV. I. Role of T cell activation and expression of the T4 antigen. J. Immunol. 1985;135:3151-3162.
23. Mitchell WM, Ding L, and Gabriel J: Inactivation of a common epitope responsible for the induction of antibody-dependent enhancement of HIV. AIDS 1998;12:147-156.
24. Mitchell WM, Torres J, Johnson PR, Hirsch V, Yilma T, Gardner MB, and Robinson WE Jr: Antibodies to the putative SIV infection-enhancing domain diminish beneficial effects of an SIV gp160 vaccine in rhesus macaques. AIDS 1995;9:27-34.
25. Montefiori DC, Murphey-Corb M, Desrosiers RC, and Daniel MD: Complement-mediated, infection-enhancing antibodies in plasma from vaccinated macaques before and after inoculation with live simian immunodeficiency virus. J. Virol. 1990;64:5223-5225.
26. Montefiori DC, Robinson WE Jr, Modliszewski A, and Mitchell WM: Complement-mediated enhancement of HIV-1 infection reverses the anti-HIV activity of castanospermine. Ann. N.Y. Acad. Sci. 1990;616:572-574.
27. Montefiori DC, Robinson WE Jr, Schuffman SS, and Mitchell WM: Evaluation of antiviral drugs and neutralizing antibodies against human immunodeficiency virus by a rapid and sensitive microtiter infection assay. J. Clin. Microbiol. 1988;26:231-235.
28. Montefiori DC, Stewart K, Ahearn JM, Zhou J, and Zhou J: Complement-mediated binding of naturally glycosylated and glycosylation modified human immunodeficiency virus type 1 to human CR2 (CD21). J. Virol. 1993;67:2699-2706.
29. Montefiori DC, Zhou J, and Shaff DI: CD4-independent binding of HIV-1 to the B lymphocyte receptor CR2 (CD21) in the presence of complement and antibody. Clin. Exp. Immunol. 1992;90:383-389.
30. + T lymphocytes enhances viral replication in HIV-infected cells. Clin. Exp. Immunol. 1996;106:297-303.
31. O'Doherty U, Swiggard WJ, Jeyakumar D, McGain D, and Malim MH: A sensitive, quantitative assay for human immunodeficiency virus type 1 integration. J. Virol. 2002;76:10942-10950.
32. Poiesz BJ, Ruscetti FW, Gazdar AF, Bunn PA, Minna JD, and Gallo RC: Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc. Natl. Acad. Sci. U.S.A. 1980;77:7415-7419.
33. Prohaszka Z, Nemes J, Hidvegi T, Toth FD, Kerekes K, Erdei A, Szabo J, Ujhelyi E, Thielens N, Dierich MP, Spath P, Ghebrehiwet B, Hampl H, Kiss J, Arlaud G, and Fust G: Two parallel routes of the complement-mediated antibody-dependent enhancement of HIV-1 infection. AIDS 1992;11:949-959.
34. Reinke RA, King PJ, Victoria JG, McDougall BR, Ma G, Mao Y, Reinecke MG, and Robinson WE Jr: Dicaffeoyltartaric acid analogues inhibit human immunodeficiency virus type 1 (HIV-1) integrase and HIV-1 replication at non-toxic concentrations. J. Med. Chem. 2002;45:3669-3683.
35. Robinson WE Jr, Montefiori DC, and Mitchell WM: Antibody dependent enhancement of human immunodeficiency virus type 1 infection. Lancet 1988;i:790-794.
36. Robinson WE Jr: Enhancing antibody and its role in acquired immunodeficiency syndrome. West. J. Med. 1993;158:297-298.
37. Robinson WE Jr, Gorny MK, Xu JY, Mitchell WM, and Zolla-Pazner S: Two immunodominant domains of gp41 bind antibodies which enhance human immunodeficiency virus type 1 infection in vitro. J. Virol. 1991;65:4169-4176.
38. Robinson WE Jr, Kawamura T, Gorny MK, Lake D, Xu JY, Matsumoto Y, Sugano T, Masuho Y, Mitchell WM, Hersh E, et al.: Human monoclonal antibodies to the human immunodeficiency virus type 1 (HIV-1) transmembrane glycoprotein gp41 enhance HIV-1 infection in vitro. Proc. Natl. Acad. Sci. U.S.A. 1990;87:3185-3189.
39. Robinson WE Jr, Kawamura T, Lake D, Masuho Y, Mitchell WM, and Hersh EM: Antibodies to the primary immunodominant domain of human immunodeficiency virus type 1 (HIV-1) glycoprotein gp41 enhance HIV-1 infection in vitro. J. Virol. 1990;64:5301-5305.
40. Robinson WE Jr, and Mitchell WM: Neutralization and enhancement of in vitro and in vivo HIV and simian immunodeficiency virus infections. AIDS 1990;4(Suppl. 1): S151-S162.
41. Robinson WE Jr, Montefiori DC, Gillespie DH, and Mitchell WM: Complement-mediated, antibody-dependent enhancement of HIV-1 infection in vitro is characterized by increased protein and RNA syntheses and infectious virus release. J. Acquir. Immune Defic. Syndr. 1989;2:33-42.
42. Robinson WE Jr, Montefiori DC, and Mitchell WM: Complement-mediated antibody-dependent enhancement of HIV-1 infection requires CD4 and complement receptors. Virology 1990;175:600-604.
43. Robinson WE Jr, Montefiori DC, and Mitchell WM: Will antibody-dependent enhancement of HIV-1 infection be a problem with AIDS vaccines? Lancet 1988;i:830-831.
44. Robinson WE Jr, Montefiori DC, Mitchell WM, Prince AM, Alter HJ, Dreesman GR, and Eichberg JW: Antibody-dependent enhancement of human immunodeficiency virus type 1(HIV-1) infection in vitro by serum from HIV-1 infected and passively immunized chimpanzees. Proc. Natl. Acad. Sci. U.S.A. 1989;86:4710-4714.
45. Staprans SI, Barry AP, Silvestri G, Safrit JT, Kozyr N, Sumpter B, Nguyen H, McClure H, Montefiori D, Cohen JI, and Feinberg MB: Enhanced SIV replication and accelerated progression to AIDS in macaques primed to mount a CD4 T cell response to the SIV envelope protein. Proc. Natl. Acad. Sci. U.S.A. 2004;101:13026-13031.
46. Stoiber H, Ebenbichler C, Schneider R, Janatova J, and Dierich MP: Interaction of several complement proteins with gp120 and gp41, the two envelope glycoproteins of HIV-1. AIDS 1995;9:12-26.
47. Stoiber H, Schneider R, Janatova J, and Dierich MP: Human complement proteins C3b, C4b, Factor H and Properdin react with specific sites in gp120 and gp41, the envelope proteins of HIV-1. Immunobiology 1995;193:98-113.
48. Stoiber H, Speth C, and Dierich MP: Role of complement in the control of HIV dynamics and pathogenesis. Vaccine 2003;21(Suppl. 2):S77-S82.
49. Subbramanian RA, Xu J, Toma E, Morisset R, Cohen EA, Menezes J, and Ahmad A: Comparison of human immunodeficiency virus (HIV)-specific infection-enhancing and inhibiting antibodies in AIDS patients. J. Clin. Microbiol. 2002;40:2141-2146.
50. Szabo J, Prohaszka Z, Toth FD, Gyuris A, Segesdi J, Banhegyi D, Ujhelyi E, Minarovits J, and Fust G: Strong correlation between the complement-mediated antibody-dependent enhancement of HIV-1 infection and plasma viral load. AIDS 1999;13:1841-1849.
51. Takada A, and Kawaoka Y: Antibody-dependent enhancement of viral infection: Molecular mechanisms and in vivo implications. Rev. Med. Virol. 2003;13:387-398.
52. Thieblemont N, Haeffner-Cavaillon N, Weiss L, Maillet F, and Kazatchkine MD: Complement activation by gp160 glycoprotein of HIV-1. AIDS Res. Hum. Retroviruses 1993;9:229-233.
53. Thielens N, Bally I, Ebenbichler C, Dierich M, and Arlaud G: Further characterization of the interaction between the C1q subcomponent of human C1 and the transmembrane envelope glycoprotein gp41 of HIV-1. J. Immunol. 1993;151:6583-6592.
54. Victoria JG, Lee DJ, McDougall BR, and Robinson WE Jr: Replication kinetics for divergent type 1 human immunodeficiency viruses using quantitative SYBR green I real-time polymerase chain reaction. AIDS Res. Hum. Retroviruses 2003;19:865-874.
55. Zack JA, Arrigo SJ, Weitsman SR, Go AS, Haislip A, and Chen IS: HIV-1 entry into quiescent primary lymphocytes: Molecular analysis reveals a labile, latent viral structure. Cell 1990;61:213-222.